IASIC Speaker Series Presents Cannabis Use and the Incidence of Psychotic Disorders

The International Academy on the Science and Impact of Cannabis (IASIC) is excited to present the IASIC Speaker Series. Presented free of charge, this ongoing educational seminar series will focus on the science, data and peer-reviewed research surrounding marijuana and will be led by international medical experts. This non-partisan and non-political series is continually developed, organized, and guided by doctors.

Session: Cannabis Use and the Incidence of Psychotic Disorders: What should we consider before prescribing medicinal cannabis?
Presented By: Marta Diforti, MD, PhD
Date: Friday, January 14, 2022
Time: 11:30AM Eastern/8:30AM Pacific
Price: FREE

Cannabis is used daily by some 200 million people worldwide, and its use and potency have increased in many countries; for example, my group has shown that high potency types have taken over 96% of the London “street” market. Furthermore, the spread of laws legalizing cannabis for medicinal or recreational use has been accompanied by more relaxed attitudes towards cannabis. Cross-sectional and prospective epidemiological studies, as well as biological investigations, demonstrate a causal link between cannabis use and psychotic disorder, especially of a paranoid type. Furthermore, our research has shown a) a dose-response association with the highest odds of psychotic disorder in the heaviest cannabis users, b) high potency types carry the greatest risk for psychotic disorder, c) patterns of cannabis use have a major impact on the incidence of psychotic disorder across Europe. High potency cannabis types have high concentrations of delta-9-tetrahydrocannabinol (THC) and virtually no cannabidiol (CBD), which, in experimental studies of healthy volunteers ameliorates the psychotogenic effect of THC. A minority of cannabis users develop clinical psychosis, but it is unclear what proportion of heavy users develop minor psychotic symptoms and paranoia in particular. Therefore, in this talk, I shall present the above evidence and discuss how they might inform how and if we can move to safely prescribe cannabis for medicinal use.

Register For This FREE Session


View Upcoming Speakers

Like this article?

Share on facebook
Share on Facebook
Share on twitter
Share on Twitter
Share on linkedin
Share on Linkdin
Share on pinterest
Share on Pinterest

Leave a comment

Related Posts

Sentinel Surveillance of Substance-Related Poisonings in Canada: Spotlight on Cannabis

Substance-related poisonings and injuries in Canada have received increasing attention in recent years due to emerging public health concerns, such as the opioid overdose crisis, the introduction of synthetic cannabinoids to the illicit market and the emergence of electronic cigarettes/vaping products on the Canadian market. Furthermore, there has been a general increase in substance-related hospitalizations

Changes in Rates of Hospitalizations due to Cannabis Harms in Ontario, Canada Before the Legalization of Nonmedical Cannabis: Retrospective Population-level Study Between 2003 and 2017

There are distinct patterns of hospitalizations due to cannabis harms in different priority populations. Young women aged 15 to 24 are a key demographic that is disproportionately burdened with a rapid increase in hospitalizations due to cannabis harms. Jurisdictions considering new approaches to cannabis control policy and addiction services should consider the rising burden of

Cannabis and Psychosis: Recent Epidemiological Findings Continuing the “Causality Debate”

Nonmedical (“recreational”) cannabis use and cannabis laws have changed over the past two decades in the United States (1) and the rest of the world (2). Increasing use, especially among the young, coupled with the increasing potency of cannabis (higher delta-9-tetrahydrocannabinol [THC] content) during this period (3), has raised concerns about the long-term health impact

Scroll to Top